Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
02:40:41 EDT Fri 03 May 2024
Enter Symbol
or Name
USA
CA



News for U:CDTX from 2023-05-04 to 2024-05-03 - 33 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-26 08:00U:CDTXNews ReleaseCidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024
2024-04-24 16:05U:CDTXNews ReleaseCidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million
2024-04-24 16:01U:CDTXNews ReleaseCidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline
2024-04-22 17:11U:CDTXNews ReleaseCidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
2024-04-22 17:06U:CDTXNews ReleaseCidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice
2024-04-22 08:50U:CDTXNews ReleaseCidara Therapeutics Announces Reverse Stock Split
2024-04-05 15:00U:CDTXNews ReleaseCidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024
2024-03-06 08:00U:CDTXNews ReleaseCidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association dor Cancer Research (AACR) Annual Meeting 2024
2024-02-12 08:00U:CDTXNews ReleaseCidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO
2024-01-29 16:30U:CDTXNews ReleaseCidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults
2023-12-22 07:30U:CDTXNews ReleaseCidara Therapeutics Announces European Approval of REZZAYO ‚ ® (rezafungin) for the Treatment of Invasive Candidiasis in Adults
2023-12-07 08:00U:CDTXNews ReleaseCidara Therapeutics Presents New Promising Preclincal Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress
2023-12-06 08:00U:CDTXNews ReleaseCidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China
2023-11-30 08:00U:CDTXNews ReleaseCidara Therapeutics to Present New Preclinical Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress
2023-11-20 08:00U:CDTXNews ReleaseCidara Therapeutics Named as a San Diego Metro Area Top Workplace
2023-11-03 12:00U:CDTXNews ReleaseCidara Therapeutics Presents Preclinical Data on Novel Drug-Fc Conjugate CBO421 at SITC ¢ € ™s 38 ¡ µ — Š ° Annual Meeting
2023-11-02 16:15U:CDTXNews ReleaseCidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
2023-10-13 10:34U:CDTXNews ReleaseCidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults(1)
2023-10-11 08:30U:CDTXNews ReleaseCidara Therapeutics Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023
2023-09-29 16:52U:CDTXNews ReleaseCidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-09-27 08:00U:CDTXNews ReleaseCidara Therapeutics to Present New Data on Novel drug-Fc conjugate CD388 at IDWeek 2023
2023-09-07 08:00U:CDTXNews ReleaseCidara Therapeutics to Host Virtual Research & Development Day on its Cloudbreak ‚ ® Development Pipeline on September 21, 2023
2023-09-06 16:05U:CDTXNews ReleaseCidara to Present at the 25th Annual H.C. Wainwright Global Investment Conference
2023-09-06 08:00U:CDTXNews ReleaseCidara Therapeutics Announces Janssen ¢ € ™s Election to Proceed Under its License Agreement Relating to Novel Drug-Fc Conjugates Targeting Influenza
2023-08-16 08:00U:CDTXNews ReleaseCidara Therapeutics Announces Appointment of Nicole Davarpanah, M.D., J.D., as Senior Vice President of Translational Research & Development
2023-08-03 16:08U:CDTXNews ReleaseCidara Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
2023-07-31 16:30U:CDTXNews ReleaseCidara Therapeutics Provides Update on REZZAYO ¢ „ ¢ (rezafungin for injection)
2023-07-20 17:00U:CDTXNews ReleaseCidara Therapeutics Provides Update on Status of Ongoing CD388 Influenza Program
2023-06-26 08:00U:CDTXNews ReleaseCidara Therapeutics Added to Russell Microcap ‚ ® Index
2023-06-22 08:00U:CDTXNews ReleaseCidara Therapeutics Receives U.S. FDA Fast Track Designation for CD388, a Novel Drug-Fc Conjugate Targeting Influenza A and B
2023-06-20 09:56U:CDTXNews ReleaseCidara Therapeutics to Present Ongoing Development of Drug-Fc Conjugates (DFC) Including CD73-Targeting DFC From Its Cloudbreak ‚ ® Platform at Adenosine-Pathway Targeted Cancer Immunotherapy Summit
2023-06-13 08:00U:CDTXNews ReleaseCidara Therapeutics to Present at Adenosine Pathway Targeted Cancer Immunotherapy Summit
2023-05-11 16:38U:CDTXNews ReleaseCidara Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results